艾美捷CpG ODN丨ODN 2006 (TLRGRADE)文献参考: T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients: H.S. Kuehn, et al.; J. Exp. Med. 218, e20211118 (2021), Abstract; Human blood myeloid and plasmacytoid dendritic c...
Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity: J.J.P. van Beek, et al.; Oncoimmunology 5, e1227902 (2016), Application(s): Human Dendritic Cells stimulation, 相关研究: PBS(无内毒素)(无菌) ALX-505-007 ODN 2006...
5. Krieg A.M.et al., 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):546-9. Figures Species-driven TLR9 differential responses NF-κB response induced by ODN 2006 IRF response induced by ODN 2006 ...
上海玉博生物科技有限公司做为invivogen代理商之产品tlrl-2006-ODN 2006 (ODN 7909) 200 µg的产品销售公司,专业经营原装进口抗体(单克隆、多克隆)、重组蛋白、检测试剂盒、标准品、细胞因子、胎牛血清、细胞培养类等生物试剂以及耗材。 玉博生物致力于成为科研试剂采购一体化解决方案提供商! 1,货品多且全,目前...
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):546-9. Figures Detection of ODN 2006 FITC by flow cytometry Back to the top Specifications Synonyms: ODN 7909, PF_3512676 Specificity: human TLR9 agonist Working concentration: 1 - 5 μM ODN 2006 ...
T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients: H.S. Kuehn, et al.; J. Exp. Med. 218, e20211118 (2021), Abstract; Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in...
T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients: H.S. Kuehn, et al.; J. Exp. Med. 218, e20211118 (2021), Abstract; Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in...
Previously, we demonstrated that a CpG ODN containing the GTCGTT motif was optimal for stimulating bovine B cell proliferation, and induced IL-6, IL-12 and IFN-纬 production by peripheral blood mononuclear cells (PBMC). The current study was designed to test the hypothesis that the nuclease ...
Recent studies have demonstrated the benefit of combining CpG ODN2006 with α-IgM antibodies to obtain optimal B cell activation in vitro. In this study, we expanded the knowledge of how both agents affect other types of peripheral blood mononuclear cells (PBMCs), thereby highlighting beneficial ...
Recent studies have demonstrated the benefit of combining CpG ODN2006 with α-IgM antibodies to obtain optimal B cell activation in vitro. In this study, we expanded the knowledge of how both agents affect other types of peripheral blood mononuclear cells (PBMCs), thereby highlighting beneficial ...